MAPT and Alzheimer disease: In particular, younger patients showed significantly lower levels of inflammatory molecules (YKL-40), of biomarkers reflecting axonal damage (NfL, pNfH) and AD-related molecules (t-Tau and p-Tau), independently from disease duration and sex.